Coronary artery bypass graft vs. percutaneous coronary angioplasty: CABG on the rebound?

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Health Economics

Background:

• Coronary artery bypass grafting (CABG) has been the traditional gold standard for complex coronary artery disease (CAD).
• Percutaneous coronary intervention (PCI), particularly with drug-eluting stents (DES), has emerged as an alternative treatment modality.
• The clinical and economic benefits of CABG versus PCI with DES require ongoing evaluation.

Purpose of the Study:

• To compare the clinical and economic benefits of CABG versus PCI with DES.
• To evaluate the efficacy of DES in complex CAD scenarios traditionally managed by CABG.
• To assess the cost-effectiveness of different revascularization strategies.

Main Methods:

• Review of current studies and meta-analyses comparing CABG and PCI with DES.
• Analysis of clinical outcomes including survival and reintervention rates.
• Health economic evaluations of medical therapy, CABG, and PCI.

Main Results:

• CABG demonstrates superior survival and freedom from reintervention for patients with proximal left anterior descending, multivessel, and left main-stem CAD.
• These benefits are amplified in diabetic patients.
• Health economic analyses support CABG and medical therapy as cost-effective, while PCI is not.
• DES do not improve survival or reduce myocardial infarction risk compared to bare metal stents and increase stent thrombosis risk.

Conclusions:

• Evidence strongly favors CABG for specific complex CAD patient groups, including diabetics and those with left main-stem disease.
• The justification for certain PCI vs. CABG trials in these populations is questioned.
• A multidisciplinary team approach is essential for optimal CAD management.